Kyowa Kirin Co., Ltd.

This study tests whether KHK4951 eye drops can safely improve vision in people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. About 180 participants will use the drops or a placebo for several months. The goal is to see if the drops reduce fluid…

This Phase 2 trial tests whether KHK4951 eye drops can improve vision in people with diabetic macular edema (DME), a leading cause of blindness. About 150 participants will receive either the eye drops or standard injections. The goal is to see if the drops can reduce swelling an…

This early-stage study tests a new drug called KK4277 in healthy volunteers and people with lupus (SLE or CLE). The main goal is to check safety and how the body processes the drug. It is too early to know if it works, but results will guide future research.

This phase 2 study tests an oral drug called ME-401 in 61 Japanese adults with a slow-growing form of non-Hodgkin's lymphoma that has returned or not responded to at least two prior treatments. The drug is taken daily for the first two months, then on a weekly schedule. Researche…

This study follows 36 patients with aplastic anemia who previously received romiplostim in earlier trials. Researchers will monitor blood cell counts and safety for up to 5 years to see if benefits last and to check for any new health issues. The goal is to better understand the …

This study follows 226 people with X-linked hypophosphatemia (XLH) for up to 10 years. Researchers will collect data on height, walking ability, fractures, and overall health to better understand how the disease progresses and affects daily life. No new treatment is being tested;…